NCT00154336CompletedPhase 2
3-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety & Tolerability of Imatinib 400 mg Daily in Combination With Methotrexate (MTX)Compared to MTX Alone in the Treatment of Rheumatoid Arthritis (RA).
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 50
- Locations
- 2
- Primary Endpoint
- Efficacy of imatinib in combination with MTX in pts with active RA by assessing response to treatment(ACR20) after 3 mos compared to MTX alone
Study Overview
Brief Summary
Imatinib is a member of a new class of drugs known as signal transduction inhibitors. The purpose of this study is to evaluate the efficacy, safety and tolerability of imatinib in the treatment of rheumatoid arthritis in combination with methotrexate in patients who do not respond satisfactorily to standard treatment, e.g. methotrexate.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •With a diagnosis of RA classified by ACR 1987 revised criteria with symptoms for at least 6 months
- •Functional status class I, II, III according to the ACR 1991 revised classification criteria
- •Patients have to have been treated with MTX at the maximum tolerated dose for at least 3 months, and be on a stable dose and route of administration for at least 2 months prior to study entry
- •Disease activity criteria of minimum 6 out of 28 tender and swollen joints at baseline
Exclusion Criteria
- •With current use of DMARDs other than MTX. DMARDs include but are not limited to: biologic agents, thiolates (D-penicillamine, thiopronine), sulfasalazine, gold compounds, antimalarials, cyclosporine A, azathioprine, leflunomide and alkylating agents such as cyclophosphamide
- •With any DMRAD treatment used in combination with methotrexate within 1 month prior to study entry. In case of infliximab and leflunomide, a washout period of 2 months is required
- •With any therapy by intra-articular injection, including intra-articular corticosteroid use within 1 month prior to study entry
- •Other protocol-defined inclusion/exclusion criteria may apply.
Arms & Interventions
Imatinib 400mmg OD +MTX
Active Comparator
Intervention: Imatinib (Drug)
Imatinib 400mmg OD +MTX
Active Comparator
Intervention: Methotrexate (Drug)
Imatinib Placebo + MTX
Placebo Comparator
Intervention: Methotrexate (Drug)
Imatinib Placebo + MTX
Placebo Comparator
Intervention: Imatinib Placebo (Drug)
Outcomes
Primary Outcomes
Efficacy of imatinib in combination with MTX in pts with active RA by assessing response to treatment(ACR20) after 3 mos compared to MTX alone
Overall safety and tolerability of imatinib in combination with MTX in pts with active RA over 3 mos compared to MTX alone.
Secondary Outcomes
- Determine time of onset of clinical response to imatinib in combination with MTX
- Efficacy of imatinib in combination with MTX by assessing the response to treatment (ACR50 and ACR70 criteria; DAS28/EULAR28) after 3 mos compared to MTX alone
- Effect of imatinib in combination with MTX on ACR components after 3 mos compared to MTX alone
- Effect of imatinib in combination with MTX on rheumatoid factor concentrations
- Determine retention on treatment of imatinib in combination with MTX over 3 mos
- Assess pt's quality of life by means of the Euro QoL 50 Health Questionnaire
- Assess in a subset of pts pharmacokinetics of imatinib and MTX and their potential interactions when co-administered
- Assess pharmacodynamic effect of imatinib in combination with MTX on liver enzymes, hematology and kidney function
- Explore potential for RA and drug-specific biomarkers
- Explore decrease in synovitis by means of ultrasound in a sub-set of patients.
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic MelanomaMetastatic MelanomaNCT00881049Peking University1
Unknown
Phase 3
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic PhaseChronic Myeloid LeukemiaNCT00327262Central European Leukemia Study Group240
Not yet recruiting
Phase 3
Masitinib in Patients With Mild Alzheimer's DiseaseAlzheimer DiseaseNCT05564169AB Science600
Completed
Phase 3
Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive dose-escalation (JALSG CML207study)Previously untreated Chronic-phase chronic myelogenous leukemiaJPRN-UMIN000000823Japan Adult Leukemia Study Group240
Completed
Phase 3
Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)Chronic Myeloid LeukemiaNCT00514488University of Bologna